AAAAAA

   
Results: 1-23 |
Results: 23
Standardization of food allergen extracts for skin prick test
Authors: Hansen, KS Bindslev-Jensen, C Skov, PS Sparholt, SH Hansen, GN Niemeijer, NR Malling, HJ Poulsen, LK
Citation: Ks. Hansen et al., Standardization of food allergen extracts for skin prick test, J CHROMAT B, 756(1-2), 2001, pp. 57-69
Gunnar Bendixen
Authors: Malling, HJ
Citation: Hj. Malling, Gunnar Bendixen, ALLERGY, 56(6), 2001, pp. 465-465
Recommendations
Authors: Bousquet, J Ait-Khaled, N Annesi-Maesano, I Baena-Cagnani, C Bateman, E Bonini, S Canonica, GW Carlsen, KH Demoly, P Durham, SR Enarson, D Fokkens, WJ van Wijk, RG Howarth, P Ivanova, NA Kemp, JP Klossek, JM Lockey, RF Lund, V Mackay, I Malling, HJ Meltzer, EO Mygind, N Okunda, M Pawankar, R Price, D Scadding, GK Simons, FER Szczeklik, A Valovirta, E Vignola, AM Wang, DY Warner, JO Weiss, KB
Citation: J. Bousquet et al., Recommendations, J ALLERG CL, 108(5), 2001, pp. S147-S334
CXCR3 expression on CD34(+) hemopoietic progenitors induced by granulocyte-macrophage colony-stimulating factor: II. Signaling pathways involved
Authors: Jinquan, T Anting, L Jacobi, HH Glue, C Jing, C Ryder, LP Madsen, HO Svejgaard, A Skov, PS Malling, HJ Poulsen, LK
Citation: T. Jinquan et al., CXCR3 expression on CD34(+) hemopoietic progenitors induced by granulocyte-macrophage colony-stimulating factor: II. Signaling pathways involved, J IMMUNOL, 167(8), 2001, pp. 4405-4413
Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment
Authors: Mellerup, MT Hahn, GW Poulsen, LK Malling, HJ
Citation: Mt. Mellerup et al., Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment, CLIN EXP AL, 30(10), 2000, pp. 1423-1429
Minimising the risks of allergen-specific injection immunotherapy
Authors: Malling, HJ
Citation: Hj. Malling, Minimising the risks of allergen-specific injection immunotherapy, DRUG SAFETY, 23(4), 2000, pp. 323-332
Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. I. Efficacy estimated by a model reducing the bias of annual differences in pollen counts
Authors: Winther, L Malling, HJ Moseholm, L Mosbech, H
Citation: L. Winther et al., Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. I. Efficacy estimated by a model reducing the bias of annual differences in pollen counts, ALLERGY, 55(9), 2000, pp. 818-826
Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects
Authors: Winther, L Malling, HJ Mosbech, H
Citation: L. Winther et al., Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects, ALLERGY, 55(9), 2000, pp. 827-835
Bacterial vaccines: anything but placebo
Authors: Malling, HJ
Citation: Hj. Malling, Bacterial vaccines: anything but placebo, ALLERGY, 55(3), 2000, pp. 214-218
Inhaled and nasal corticosteroids: safety aspects
Authors: Passalacqua, G Albano, M Canonica, GW Bachert, C Van Cauwenberge, P Davies, RJ Durham, SR Kontou-Fili, K Horak, F Malling, HJ
Citation: G. Passalacqua et al., Inhaled and nasal corticosteroids: safety aspects, ALLERGY, 55(1), 2000, pp. 16-33
CXCR3 expression and activation of eosinophils: Role of IFN-gamma-inducible protein-10 and monokine induced by IFN-gamma
Authors: Tan, JQ Chen, J Jacobi, HH Reimert, CM Millner, A Sha, Q Hansen, JB Dissing, S Malling, HJ Skov, PS Poulsen, LK
Citation: Jq. Tan et al., CXCR3 expression and activation of eosinophils: Role of IFN-gamma-inducible protein-10 and monokine induced by IFN-gamma, J IMMUNOL, 165(3), 2000, pp. 1548-1556
CXC chemokine receptor 4 expression and stromal cell-derived factor-1 alpha-induced chemotaxis in CD4(+) T lymphocytes are regulated by interleukin-4andinterleukin-10
Authors: Jinquan, T Quan, S Jacobi, HH Madsen, HO Glue, C Skov, PS Malling, HJ Poulsen, LK
Citation: T. Jinquan et al., CXC chemokine receptor 4 expression and stromal cell-derived factor-1 alpha-induced chemotaxis in CD4(+) T lymphocytes are regulated by interleukin-4andinterleukin-10, IMMUNOLOGY, 99(3), 2000, pp. 402-410
CXC chemokine receptor 3 expression on CD34(+) hematopoietic progenitors from human cord blood induced by granulocyte-macrophage colony-stimulating factor: chemotaxis and adhesion induced by its ligands, interferon gamma-inducible protein 10 and monokine induced by interferon gamma
Authors: Tan, JQ Quan, S Jacobi, HH Jing, C Millner, A Jensen, B Madsen, HO Ryder, LP Svejgaard, A Malling, HJ Skov, PS Poulsen, LK
Citation: Jq. Tan et al., CXC chemokine receptor 3 expression on CD34(+) hematopoietic progenitors from human cord blood induced by granulocyte-macrophage colony-stimulating factor: chemotaxis and adhesion induced by its ligands, interferon gamma-inducible protein 10 and monokine induced by interferon gamma, BLOOD, 96(4), 2000, pp. 1230-1238
Who position paper on oral (sublingual) immunotherapy - Response
Authors: Lockey, RR Bousquet, J Malling, HJ
Citation: Rr. Lockey et al., Who position paper on oral (sublingual) immunotherapy - Response, ANN ALLER A, 83(5), 1999, pp. 423-424
Allergen immunotherapy: Therapeutic vaccines for allergic diseases - WHO position paper - Geneva, January 27-29, 1991 - Preface
Authors: Bousquet, J Lockey, RF Malling, HJ
Citation: J. Bousquet et al., Allergen immunotherapy: Therapeutic vaccines for allergic diseases - WHO position paper - Geneva, January 27-29, 1991 - Preface, REV FR ALLE, 39(5), 1999, pp. 399-442
Allergen-specific immunotherapy in the management of allergic rhinitis
Authors: Malling, HJ
Citation: Hj. Malling, Allergen-specific immunotherapy in the management of allergic rhinitis, ALLERGY, 54, 1999, pp. 35-36
Allergen-specific immunotherapy. Present state and directions for the future
Authors: Malling, HJ
Citation: Hj. Malling, Allergen-specific immunotherapy. Present state and directions for the future, ALLERGY, 54, 1999, pp. 30-33
Histamine and tryptase in nasal lavage fluid after allergen challenge: Effect of 1 week of pretreatment with intranasal azelastine or systemic cetirizine
Authors: Jacobi, HH Skov, PS Poulsen, LK Malling, HJ Mygind, N
Citation: Hh. Jacobi et al., Histamine and tryptase in nasal lavage fluid after allergen challenge: Effect of 1 week of pretreatment with intranasal azelastine or systemic cetirizine, J ALLERG CL, 103(5), 1999, pp. 768-772
Cutting edge: Expression of the NF of activated T cells in eosinophils: Regulation by IL-4 and IL-5
Authors: Tan, JQ Quan, S Jacobi, HH Reimert, CM Millner, A Hansen, JB Thygesen, C Ryder, LP Madsen, HO Malling, HJ Poulsen, LK
Citation: Jq. Tan et al., Cutting edge: Expression of the NF of activated T cells in eosinophils: Regulation by IL-4 and IL-5, J IMMUNOL, 163(1), 1999, pp. 21-24
Meta-analysis of specific immunotherapy in patients with allergic rhinoconjunctivitis
Authors: Klimek, L Malling, HJ
Citation: L. Klimek et Hj. Malling, Meta-analysis of specific immunotherapy in patients with allergic rhinoconjunctivitis, HNO, 47(7), 1999, pp. 602
Allergen immunotherapy - Therapeutic vaccines for allergic diseases
Authors: Bousquet, J Lockey, RF Malling, HJ
Citation: J. Bousquet et al., Allergen immunotherapy - Therapeutic vaccines for allergic diseases, LUNG BIOL H, 136, 1999, pp. 89-98
International recommendations
Authors: Malling, HJ
Citation: Hj. Malling, International recommendations, LUNG BIOL H, 136, 1999, pp. 263-279
Allergen immunotherapy: therapeutic vaccines for allergic diseases
Authors: Bousquet, J Lockey, R Malling, HJ Alvarez-Cuesta, E Canonica, GW Chapman, MD Creticos, PJ Dayer, JM Durham, SR Demoly, P Goldstein, RJ Ishikawa, T Ito, K Kraft, D Lambert, PH Lowenstein, H Muller, U Norman, PS Reisman, RE Valenta, R Valovirta, E Yssel, H
Citation: J. Bousquet et al., Allergen immunotherapy: therapeutic vaccines for allergic diseases, ANN ALLER A, 81(5), 1998, pp. 401-405
Risultati: 1-23 |